Caplin Point Laboratories Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Caplin Point Laboratories Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Debt due within a year is covered 918.0 times by its yearly operating cash. Higher than almost all Healthcare companies in India.
- Growth Efficiency Ratio: Sales grew 49% in 3 years; of every extra ₹100 of sales, ₹37 became extra profit. Higher than 85% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹78Over the last 3 years, every ₹100 of reported profit came with ₹78 of operating cash.
Lower than 74% of Healthcare companies in India.
Self-Funding Ratio
2.2×Over the last 3 years its own operating cash covered its investment spending (capex) 2.2 times.
Higher than 70% of Healthcare companies in India.
Cash Locked Ratio
₹42For every ₹100 of sales, ₹42 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹32 tied up three years earlier.
More money tied up than 82% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹37Sales grew 49% in 3 years; of every extra ₹100 of sales, ₹37 became extra profit.
Higher than 85% of Healthcare companies in India.
Asset Productivity Ratio
+49% / +85%In 3 years sales changed by +49% while total assets changed by +85%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
918.0×Debt due within a year is covered 918.0 times by its yearly operating cash.
Higher than almost all Healthcare companies in India.
Cash Cushion Ratio
+6%Cash, after subtracting all debt, equals 6% of its market value (net cash).
Higher than 83% of Healthcare companies in India.
Tangible Assets Ratio
99%Of every ₹100 the company owns, ₹99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 58% of Healthcare companies in India.
Tangible Net Worth Ratio
98%Of every ₹100 of net worth, ₹98 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 62% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Caplin Point Laboratories Limited owes ₹0.10 for every ₹1 it owns. Net profit rose 20% in the year to Mar 2026, and grew 19% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
25.8Investors pay ₹25.8 for every ₹1 of Caplin Point Laboratories Limited's yearly profit, lower than 72% of Healthcare companies in India.
P/B ratio
4.77The share price is 4.77 times Caplin Point Laboratories Limited's book value per share, higher than 51% of Healthcare companies in India.
Market cap
₹17,096 CrThe total market value of all of Caplin Point Laboratories Limited's shares at today's price (share price × number of shares), larger than 77% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹3,586 CrWhat Caplin Point Laboratories Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹471.82Net worth divided by the number of shares. The share price of ₹2,249 is 4.8 times this, which is the P/B above.
Return on equity (ROE)
18.9%Caplin Point Laboratories Limited earned 18.9% on its shareholders' money over the last year, higher than 77% of Healthcare companies in India.
Owes vs Owns
0.10×Caplin Point Laboratories Limited owes ₹0.10 for every ₹1 it owns (low), lower than almost all Healthcare companies in India.
Dividend yield
0.33%Caplin Point Laboratories Limited pays 0.33% of its share price as dividends a year, lower than 55% of dividend-paying Healthcare companies in India.
Revenue growth
+13%Revenue rose 13% in the year to Mar 2026, and grew 14% a year on average over 3 years.
Profit growth
+20%Net profit rose 20% in the year to Mar 2026, and grew 19% a year on average over 3 years.
Profit margin
29.5%Caplin Point Laboratories Limited keeps ₹30 of every ₹100 of revenue as net profit.
Cash quality
0.8×Cash from Caplin Point Laboratories Limited's business was 0.8× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
798.4×Caplin Point Laboratories Limited's operating profit covered its interest costs 798.4 times in the year to Mar 2026.
Cash vs debt
Net cashCaplin Point Laboratories Limited held ₹987 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Caplin Point Laboratories Limited's P/E ratio?
Investors pay ₹25.8 for every ₹1 of Caplin Point Laboratories Limited's yearly profit, lower than 72% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Caplin Point Laboratories Limited: ₹17,096 Cr ÷ ₹3,586 Cr (31 Mar 2026) = 4.8.
What is Caplin Point Laboratories Limited's return on equity?
Caplin Point Laboratories Limited earned 18.9% on its shareholders' money over the last year, higher than 77% of Healthcare companies in India.
How much does Caplin Point Laboratories Limited owe compared with what it owns?
Caplin Point Laboratories Limited owes ₹0.10 for every ₹1 it owns (low), lower than almost all Healthcare companies in India.
Does Caplin Point Laboratories Limited pay a dividend?
Yes. Caplin Point Laboratories Limited pays 0.33% of its share price as dividends a year, lower than 55% of dividend-paying Healthcare companies in India.
Is Caplin Point Laboratories Limited's revenue growing?
Revenue rose 13% in the year to Mar 2026, and grew 14% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.